Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 312

1.

High prevalence of urogenital infection/inflammation in patients with azoospermia does not impede surgical sperm retrieval.

Pilatz A, Kilb J, Kaplan H, Fietz D, Hossain H, Schüttler CG, Diemer T, Bergmann M, Domann E, Weidner W, Wagenlehner F, Schuppe HC.

Andrologia. 2019 Aug 27:e13401. doi: 10.1111/and.13401. [Epub ahead of print]

PMID:
31456226
2.

Awareness and perception of multidrug-resistant organisms and antimicrobial therapy among internists vs. surgeons of different specialties: Results from the German MR2 Survey.

Spachmann PJ, May M, Vetterlein MW, Fritsche HM, Steffen S, Schostak M, Wagenlehner FM, Burger M, Weylandt KH, Salzberger B, Brookman-May SD, Gilfrich C; MR2 study group.

Caspian J Intern Med. 2019 Spring;10(2):132-141. doi: 10.22088/cjim.10.2.132.

3.
4.

Determination of leucocyte extracellular traps (ETs) in seminal fluid (ex vivo) in infertile patients-A pilot study.

Schulz M, Zambrano F, Schuppe HC, Wagenlehner F, Taubert A, Ulrich G, Sánchez R, Hermosilla C.

Andrologia. 2019 Oct;51(9):e13356. doi: 10.1111/and.13356. Epub 2019 Jul 9.

PMID:
31287181
5.

Associated measures to antibiotic prophylaxis in urology.

Bruyere F, Pilatz A, Boehm A, Pradere B, Wagenlehner F, Vallee M.

World J Urol. 2019 Jun 28. doi: 10.1007/s00345-019-02854-z. [Epub ahead of print]

PMID:
31254099
6.

Time to Adapt Our Practice? The European Commission Has Restricted the Use of Fluoroquinolones since March 2019.

Bonkat G, Pilatz A, Wagenlehner F.

Eur Urol. 2019 Sep;76(3):273-275. doi: 10.1016/j.eururo.2019.06.011. Epub 2019 Jun 23. No abstract available.

PMID:
31239078
7.

Urethral closure is by a musculo-elastic mechanism, not pressure transmission.

Liedl B, Sutherland S, Gunnemann A, Witczak M, Wagenlehner F.

Neurourol Urodyn. 2019 Aug;38(6):1793-1794. doi: 10.1002/nau.24064. Epub 2019 Jun 18. No abstract available.

PMID:
31215068
8.

Monocyte-derived extracellular trap (MET) formation induces aggregation and affects motility of human spermatozoa in vitro.

Schulz M, Zambrano F, Schuppe HC, Wagenlehner F, Taubert A, Gaertner U, Sánchez R, Hermosilla C.

Syst Biol Reprod Med. 2019 Jun 18:1-10. doi: 10.1080/19396368.2019.1624873. [Epub ahead of print]

PMID:
31208212
9.

Cost-effectiveness analysis of ceftazidime/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections.

Kongnakorn T, Wagenlehner F, Falcone M, Tichy E, Di Virgilio R, Baillon-Plot N, Charbonneau C.

Int J Antimicrob Agents. 2019 Jun 13. pii: S0924-8579(19)30161-X. doi: 10.1016/j.ijantimicag.2019.06.008. [Epub ahead of print]

10.

Antibiotic resistance, hospitalizations, and mortality related to prostate biopsy: first report from the Norwegian Patient Registry.

Johansen TEB, Zahl PH, Baco E, Bartoletti R, Bonkat G, Bruyere F, Cai T, Cek M, Kulchavenya E, Köves B, Mouraviev V, Pilatz A, Tandogdu Z, Tenke P, Wagenlehner FME.

World J Urol. 2019 Jun 10. doi: 10.1007/s00345-019-02837-0. [Epub ahead of print] Review.

PMID:
31183524
11.

[Orchitis].

Pilatz A, Fijak M, Wagenlehner F, Schuppe HC.

Urologe A. 2019 Jun;58(6):697-710. doi: 10.1007/s00120-019-0951-0. German.

PMID:
31111192
12.

A step further in a vaccine for Escherichia coli.

Wagenlehner FM, Naber KG.

Lancet Infect Dis. 2019 Jun;19(6):565-567. doi: 10.1016/S1473-3099(19)30069-6. Epub 2019 May 9. No abstract available.

PMID:
31079948
13.

Urinary bactericidal activity of colistin and azidothymidine combinations against mcr-1-positive colistin-resistant Escherichia coli.

Loose M, Naber KG, Hu Y, Coates A, Wagenlehner FME.

Int J Antimicrob Agents. 2019 Jul;54(1):55-61. doi: 10.1016/j.ijantimicag.2019.04.011. Epub 2019 Apr 26.

PMID:
31034939
14.

Appropriate empiric antibiotic choices in health care associated urinary tract infections in urology departments in Europe from 2006 to 2015: A Bayesian analytical approach applied in a surveillance study.

Tandogdu Z, Kakariadis ETA, Naber K, Wagenlehner F, Bjerklund Johansen TE.

PLoS One. 2019 Apr 25;14(4):e0214710. doi: 10.1371/journal.pone.0214710. eCollection 2019.

15.

Evaluation of the draft guidelines proposed by EMA and FDA for the clinical diagnosis of acute uncomplicated cystitis in women.

Alidjanov JF, Naber KG, Pilatz A, Radzhabov A, Zamuddinov M, Magyar A, Tenke P, Wagenlehner FM.

World J Urol. 2019 Apr 19. doi: 10.1007/s00345-019-02761-3. [Epub ahead of print]

PMID:
31004204
16.

Metagenomics in diagnosis and improved targeted treatment of UTI.

Dixon M, Stefil M, McDonald M, Bjerklund-Johansen TE, Naber K, Wagenlehner F, Mouraviev V.

World J Urol. 2019 Apr 3. doi: 10.1007/s00345-019-02731-9. [Epub ahead of print]

PMID:
30944967
17.

The use of oral fosfomycin-trometamol in patients with catheter-associated urinary tract infections (CAUTI): new indications for an old antibiotic?

Cai T, Cocci A, Verze P, Rizzo M, Palmieri A, Liguori G, Trombetta C, Adembri C, Carini M, Bartoletti R, Wagenlehner FM, Bonkat G, Mirone V, Bjerklund Johansen TE, Novelli A.

J Chemother. 2018 Sep;30(5):290-295. doi: 10.1080/1120009X.2018.1500110.

PMID:
30843774
18.

Once-Daily Plazomicin for Complicated Urinary Tract Infections.

Wagenlehner FME, Cloutier DJ, Komirenko AS, Cebrik DS, Krause KM, Keepers TR, Connolly LE, Miller LG, Friedland I, Dwyer JP; EPIC Study Group.

N Engl J Med. 2019 Feb 21;380(8):729-740. doi: 10.1056/NEJMoa1801467.

PMID:
30786187
19.

Reevaluation of the Acute Cystitis Symptom Score, a Self-Reporting Questionnaire. Part I. Development, Diagnosis and Differential Diagnosis.

Alidjanov JF, Naber KG, Abdufattaev UA, Pilatz A, Wagenlehner FME.

Antibiotics (Basel). 2018 Jan 15;7(1). pii: E6. doi: 10.3390/antibiotics7010006.

20.

Perioperative antibiotic prophylaxis for stone therapy.

Schnabel MJ, Wagenlehner FME, Schneidewind L.

Curr Opin Urol. 2019 Mar;29(2):89-95. doi: 10.1097/MOU.0000000000000576.

PMID:
30668554
21.

Multidisciplinary approach to prostatitis.

Magri V, Boltri M, Cai T, Colombo R, Cuzzocrea S, De Visschere P, Giuberti R, Granatieri CM, Latino MA, Larganà G, Leli C, Maierna G, Marchese V, Massa E, Matteelli A, Montanari E, Morgia G, Naber KG, Papadouli V, Perletti G, Rekleiti N, Russo GI, Sensini A, Stamatiou K, Trinchieri A, Wagenlehner FME.

Arch Ital Urol Androl. 2019 Jan 18;90(4):227-248. doi: 10.4081/aiua.2018.4.227.

22.
23.

Cefiderocol for treatment of complicated urinary tract infections.

Wagenlehner FME, Naber KG.

Lancet Infect Dis. 2019 Jan;19(1):22-23. doi: 10.1016/S1473-3099(18)30722-9. No abstract available.

PMID:
30587289
24.

Novel Antibiotics in the Treatment of Urinary Tract Infections.

Naber KG, Wagenlehner FME.

Eur Urol Focus. 2019 Jan;5(1):10-12. doi: 10.1016/j.euf.2018.11.012. Epub 2018 Dec 13.

PMID:
30555037
25.

Transurethral Resection of the Prostate: are We Following the Guidelines? - Outcomes from the Global Prevalence of Infections in Urology (GPIU) Study.

Köves B, Tenke P, Tandogdu Z, Cai T, Bogenhard F, Wullt B, Naber K, Bartoletti R, Cek M, Kulchavenya E, Perepanova T, Pilatz A, Bonkat G, Erik Bjerklund Johansen T, Wagenlehner F.

J Chemother. 2019 Feb;31(1):15-22. doi: 10.1080/1120009X.2018.1542552. Epub 2018 Dec 3.

PMID:
30508403
26.

Update on Strategies to Reduce Infectious Complications After Prostate Biopsy.

Pilatz A, Veeratterapillay R, Köves B, Cai T, Bartoletti R, Wagenlehner F, Bruyère F, Geerlings S, Bonkat G, Pradere B.

Eur Urol Focus. 2019 Jan;5(1):20-28. doi: 10.1016/j.euf.2018.11.009. Epub 2018 Nov 30. Review.

PMID:
30503175
27.

In the Line of Fire: Should Urologists Stop Prescribing Fluoroquinolones as Default?

Bonkat G, Wagenlehner F.

Eur Urol. 2019 Feb;75(2):205-207. doi: 10.1016/j.eururo.2018.10.057. Epub 2018 Nov 22.

PMID:
30471884
28.

Management of Urosepsis in 2018.

Bonkat G, Cai T, Veeratterapillay R, Bruyère F, Bartoletti R, Pilatz A, Köves B, Geerlings SE, Pradere B, Pickard R, Wagenlehner FME.

Eur Urol Focus. 2019 Jan;5(1):5-9. doi: 10.1016/j.euf.2018.11.003. Epub 2018 Nov 15.

PMID:
30448051
29.

Reliability of Symptom-Based Diagnosis of Uncomplicated Cystitis.

Alidjanov JF, Naber KG, Abdufattaev UA, Pilatz A, Wagenlehner FM.

Urol Int. 2019;102(1):83-95. doi: 10.1159/000493509. Epub 2018 Nov 12.

PMID:
30419565
30.

[Current diagnosis and treatment of sexually transmitted infections].

Hein DC, Wagenlehner FME.

Urologe A. 2018 Dec;57(12):1436-1444. doi: 10.1007/s00120-018-0803-3. Review. German.

PMID:
30377706
31.

Management of Urethritis: Is It Still the Time for Empirical Antibiotic Treatments?

Bartoletti R, Wagenlehner FME, Bjerklund Johansen TE, Köves B, Cai T, Tandogdu Z, Bonkat G.

Eur Urol Focus. 2019 Jan;5(1):29-35. doi: 10.1016/j.euf.2018.10.006. Epub 2018 Oct 11.

PMID:
30318465
33.

Preventing urinary tract infections in patients with neurogenic bladder.

Wagenlehner FME, Pilatz A.

Lancet Infect Dis. 2018 Sep;18(9):926-927. doi: 10.1016/S1473-3099(18)30284-6. Epub 2018 Jun 28. No abstract available.

34.

Serum bactericidal activity of colistin and azidothymidine combinations against mcr-1-positive colistin-resistant Escherichia coli.

Loose M, Naber KG, Hu Y, Coates A, Wagenlehner FME.

Int J Antimicrob Agents. 2018 Dec;52(6):783-789. doi: 10.1016/j.ijantimicag.2018.08.010. Epub 2018 Aug 21.

PMID:
30138665
35.

[Urogenital tuberculosis and schistosomiasis (bilharzia) : Urological challenges in displaced persons].

Naber KG, Kulchavenya E, Bichler KH, Wagenlehner FME.

Urologe A. 2018 Oct;57(10):1191-1199. doi: 10.1007/s00120-018-0760-x. Review. German.

PMID:
30135981
36.

Re: Acute Pyelonephritis in Adults.

Wagenlehner FME, Diemer T.

Eur Urol. 2018 Nov;74(5):676. doi: 10.1016/j.eururo.2018.07.014. Epub 2018 Jul 20. No abstract available.

PMID:
30037528
37.

Response to 'Aberrant expression of TdT in seminomatous germ cell neoplasia'.

Brobeil A, Wagenlehner F, Gattenlöhner S.

Virchows Arch. 2018 Sep;473(3):387. doi: 10.1007/s00428-018-2403-4. Epub 2018 Jul 6. No abstract available.

PMID:
29980856
38.

Treatment Options for Carbapenem- Resistant Gram-Negative Infections.

Fritzenwanker M, Imirzalioglu C, Herold S, Wagenlehner FM, Zimmer KP, Chakraborty T.

Dtsch Arztebl Int. 2018 May 21;115(20-21):345-352. doi: 10.3238/arztebl.2018.0345.

39.

Reevaluation of the Acute Cystitis Symptom Score, a Self-Reporting Questionnaire. Part II. Patient-Reported Outcome Assessment.

Alidjanov JF, Naber KG, Abdufattaev UA, Pilatz A, Wagenlehner FM.

Antibiotics (Basel). 2018 May 21;7(2). pii: E43. doi: 10.3390/antibiotics7020043.

40.

The role of the Acute Cystitis Symptom Score questionnaire for research and antimicrobial stewardship. Validation of the Hungarian version.

Magyar A, Alidjanov J, Pilatz A, Nagy K, Arthanareeswaran VKA, Póth S, Bécsi A, Wagenlehner FME, Naber KG, Tenke P, Köves B.

Cent European J Urol. 2018;71(1):134-141. doi: 10.5173/ceju.2018.1530. Epub 2017 Jan 22.

41.

Elevated seminal plasma estradiol and epigenetic inactivation of ESR1 and ESR2 is associated with CP/CPPS.

Nesheim N, Ellem S, Dansranjavin T, Hagenkötter C, Berg E, Schambeck R, Schuppe HC, Pilatz A, Risbridger G, Weidner W, Wagenlehner F, Schagdarsurengin U.

Oncotarget. 2018 Apr 13;9(28):19623-19639. doi: 10.18632/oncotarget.24714. eCollection 2018 Apr 13.

42.

Influence of Body Mass Index on Clinical Outcome Parameters, Complication Rate and Survival after Radical Cystectomy: Evidence from a Prospective European Multicentre Study.

Gierth M, Zeman F, Denzinger S, Vetterlein MW, Fisch M, Bastian PJ, Syring I, Ellinger J, Müller SC, Herrmann E, Gilfrich C, May M, Pycha A, Wagenlehner FM, Vallo S, Bartsch G, Haferkamp A, Grimm MO, Roigas J, Protzel C, Hakenberg OW, Fritsche HM, Burger M, Aziz A, Mayr R.

Urol Int. 2018;101(1):16-24. doi: 10.1159/000488466. Epub 2018 May 2.

PMID:
29719296
43.

In Reply.

Kranz J, Schmidt S, Lebert C, Schneidewind L, Schmiemann G, Wagenlehner F.

Dtsch Arztebl Int. 2018 Mar 16;115(11):192. doi: 10.3238/arztebl.2018.0192. No abstract available.

44.

The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients. Part II: Therapy and Prevention.

Kranz J, Schmidt S, Lebert C, Schneidewind L, Mandraka F, Kunze M, Helbig S, Vahlensieck W, Naber K, Schmiemann G, Wagenlehner FM.

Urol Int. 2018;100(3):271-278. doi: 10.1159/000487645. Epub 2018 Mar 14.

PMID:
29539622
45.

Expression of terminal deoxynucleotidyl transferase (TdT) in classical seminoma: a potential diagnostic pitfall.

Brobeil A, Wagenlehner F, Gattenlöhner S.

Virchows Arch. 2018 Mar;472(3):433-440. doi: 10.1007/s00428-018-2313-5. Epub 2018 Feb 18.

PMID:
29455318
46.

[Urosepsis].

Pletz MW, Weis S, Forstner C, Wagenlehner F.

Med Klin Intensivmed Notfmed. 2018 Mar;113(2):143-156. doi: 10.1007/s00063-018-0406-1. German.

PMID:
29442147
47.

Re: Letter to the editor.

Lebentrau S, Gilfrich C, Vetterlein MW, Schumacher H, Spachmann PJ, Brookman-May SD, Fritsche HM, Schostak M, Wagenlehner FM, Burger M, May M.

Int Urol Nephrol. 2018 May;50(5):875. doi: 10.1007/s11255-018-1808-y. Epub 2018 Feb 13. No abstract available.

PMID:
29441478
48.

The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients: Part 1.

Kranz J, Schmidt S, Lebert C, Schneidewind L, Mandraka F, Kunze M, Helbig S, Vahlensieck W, Naber K, Schmiemann G, Wagenlehner FM.

Urol Int. 2018;100(3):263-270. doi: 10.1159/000486138. Epub 2018 Jan 17.

49.

Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections.

Wagenlehner F, Nowicki M, Bentley C, Lückermann M, Wohlert S, Fischer C, Vente A, Naber K, Dalhoff A.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02317-17. doi: 10.1128/AAC.02317-17. Print 2018 Apr.

50.

[Urosepsis].

Pletz MW, Weis S, Forstner C, Wagenlehner F.

Urologe A. 2018 Jan;57(1):79-92. doi: 10.1007/s00120-017-0559-1. German.

PMID:
29322236

Supplemental Content

Loading ...
Support Center